4 High Risk COVID Patients Administered With Antibody Cocktail Therapy
Four COVID-19 patients in Kolkata received Switzerland-based Roche's Antibody Cocktail, a drug with a combination of Casirivimab and Imdevimab. Administered to patients with mild to moderate COVID-19 infections, the drug has brought silver lining for patients with comorbidities. The drug stops the virus from entering the cells hence reducing the replication of the virus. No discomfort or other health issues related to the drug have been… read-more
Tags: antibody cocktail, COVID-19 outbreak, drug, Covid-19
Courtesy: The Times of India
Antibody Cocktail For Treating COVID-19 Launched At Rs 59,750/Dose
Drug company Roche India and Cipla have jointly launched 'Antibody Cocktail' of Casirivimab and Imdevimab, for treating COVID-19 patients above 12 years of age. A single dose pack (1200mg) of the cocktail has been priced at Rs 59,750 while the multiple dose pack, meant for two patients, will cost Rs 1,19,500. As per claims, the drug can reduce fatality by 70% and shortens symptoms' duration by four days.
Tags: Roche India, Cipla, antibody cocktail, Covid-19
Courtesy: Free Press Journal